Cost-effectiveness analysis of Abciximab: A Canadian Hospital perspective

Annals of Pharmacotherapy

Volumn 32, Issue 5, 1998, Pages 536-542

  Zed, Peter J ^a,b   Frighetto, Luciana ^a,c   Sunderji, Rubina ^a,c   Marra, Carlo A ^a,c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c Vancouver Hosp and Hlth Sci Ctr

^d Clinical Services Unit Pharmaceutical Sciences Vancouver Acute Canada   (Canada)

Author keywords

Abciximab; Cost effectiveness

Indexed keywords

ABCIXIMAB; ALTEPLASE; HEPARIN; PLACEBO; STREPTOKINASE;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CANADA; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS;

EID: 0031750340     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17336     Document Type: Article

References (25)

1. Bennett JS. Mechanisms of platelet adhesion and aggregation: an update. Hosp Pract 1992;24:124-40.
2. Handin RI, Loscalzo J. Hemostasis, thrombosis, fibrinolysis and cardiovascular disease. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders, 1992:1767-89.
3. Coller BS. A new murine monoclonal antibody reports on activation dependent changes in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-8.
4. 2 fragments of murine monoclonal antibody 7E directed against human platelet glycoprotein IIb/IIIa ion patients with unstable angina pectoris. J Clin Invest 1990;86:651-9.
5. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIbz/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
6. Simoons ML, de Boer MJ, van der Brand MJBM, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, et al. Randomized trial of GPIIb/IIIa platelet receptor blocker in unstable refractory unstable angina. Circulation 1994;89:596-603.
7. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Textbook of interventional cardiology. 2nd ed. Philadelphia: WB Saunders, 1994:415-35.
8. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
9. Tenaglia AN, Fortin DF, Frid DJ, Gardner LH, Nelson CL, Tcheng JE, et al. Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. Am J Cardiol 1993;72:21-5.
10. Bittl JA. Advances in coronary angioplasty. N Engl J Med 1996;335: 1290-302.
11. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
12. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
13. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomized trial of coronary intervention with antibody against platelet glycoprotein IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
14. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
15. Ryan TJ, Faxon DP, Gunner RM, Kennedy JW, King SB, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on the Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486-502.
16. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty. Circulation 1996;94:629-35.
17. Sacristan JA, Navarro O, Huete T, Iniguez A. Cost-effectiveness of the monoclonal antibody c7E3 in high-risk coronary angioplasty in Spain. Br J Med Econ 1996;10:169-83.
18. Mason J. The generalisability of pharmacoeconomic studies. Pharmaco-Economics 1997;11:503-14.
19. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lemer RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular weight heparin vs intravenous heparin: an economic perspective. Arch Intern Med 1997;157:289-94.
20. British Columbia Medical Association Guide to Fees. Vancouver, BC: British Columbia Medical Association, 1997.
21. Frighetto L, Nickoloff D, Jewesson P. Antibiotic therapeutic interchange program: six years of experience. Hosp Formul 1995;30:92-105.
22. Magid D, Douglas JM, Schwanz S. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389-99.
23. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 1995;273:1032-8.
24. Riviere M, Wang S, Leclerc C, Fitzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. Can Med Assoc J 1997;156:991-7.
25. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.